The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms.

Authors

Amy M Egras, Thomas Jefferson University,Follow
Elena Umland, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

1-1-2010

Comments

This article has been peer reviewed. It was published in: International journal of general medicine.

2010 May 26;3:147-51.

The published version is available at PMCID: PMC2880349. Copyright © Dove Press.

Abstract

Vasomotor symptoms (VMS) are among the most bothersome complaints of postmenopausal women. To date, the most widely studied and effective treatment for VMS is hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for treatment. However, over the years, additional estrogen formulations have been developed including transdermal patches; vaginal rings, creams, and tablets; and injectable preparations. Two newer formulations are transdermal estrogen spray and estradiol topical emulsion. This review evaluates the current literature assessing the use of these two newer formulations for the treatment of VMS associated with menopause.

Recommended Citation

Egras, Amy M and Umland, Elena, "The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms." (2010). College of Pharmacy Faculty Papers. Paper 16.
https://jdc.jefferson.edu/pharmacyfp/16

PubMed ID

20531974